Development and biological evaluation of PSMA/FAP dual targeting radiotracers for prostate cancer imaging
- 16 August 2024
- journal article
- research article
- Published by Royal Society of Chemistry (RSC) in Inorganic Chemistry Frontiers
- Vol. 11 (19) , 6476-6485
Abstract
Prostate cancer (PCa) is a common malignant cancer in men with a five-year survival rate of 32%. In recent years, positron emission tomography (PET) has been widely used in clinical PCa diagnosis. In this study, we developed two novel PSMA-FAP radiotracers ([68Ga]Ga-PSMA-FAPI-01 and [68Ga]Ga-PSMA-FAPI-02) for PET/CT, aiming to develop PSMA-FAP dual-targeting radiotracers with high selectivity and favourable pharmacokinetic properties for the diagnosis of PCa. We introduced lipophilic groups, based on the glutamic acid–urea–lysine pharmacophore and linked a DOTAGA group for 68Ga labeling. [68Ga]Ga-PSMA-FAPI-01 and [68Ga]Ga-PSMA-FAPI-02 were investigated, compared with [68Ga]Ga-PSMA-11 and [68Ga]Ga-PSMA I&T. Two novel radiotracers were prepared with a radiochemical purity >95%, and excellent stability in vivo and in vitro. Novel radiotracers revealed high receptor affinity towards PSMA and FAP (Ki < 10 nM). The results of micro-PET/CT imaging and biodistribution studies demonstrated that novel radiotracers displayed excellent dual-targeting capability and favorable pharmacokinetic properties, which were also observed in human PET/CT studies. All these indicate that a dual-targeting strategy is available in designing radiotracers for tumor imaging.Keywords
Funding Information
- National Natural Science Foundation of China (22376125)
- Natural Science Foundation of Shandong Province (ZR2019BA015, ZR2023MH004)
This publication has 37 references indexed in Scilit:
- [68Ga]Ga-FAP-2286, a novel promising theragnostic approach for PET/CT imaging in patients with various type of metastatic cancersEuropean Journal of Nuclear Medicine and Molecular Imaging, 2024
- Synthesis, preclinical, and initial clinical evaluation of integrin αVβ3 and gastrin-releasing peptide receptor (GRPR) dual-targeting radiotracer [68Ga]Ga-RGD-RM26-03European Journal of Nuclear Medicine and Molecular Imaging, 2024
- Quantitation of dynamic total-body PET imaging: recent developments and future perspectivesEuropean Journal of Nuclear Medicine and Molecular Imaging, 2023
- Head-to-head comparison of different classes of FAP radioligands designed to increase tumor residence time: monomer, dimer, albumin binders, and small molecules vs peptidesEuropean Journal of Nuclear Medicine and Molecular Imaging, 2023
- Preclinical evaluation of FAP-2286 for fibroblast activation protein targeted radionuclide imaging and therapyEuropean Journal of Nuclear Medicine and Molecular Imaging, 2022
- Hybrid total-body pet scanners—current status and future perspectivesEuropean Journal of Nuclear Medicine and Molecular Imaging, 2021
- Meeting report from the Prostate Cancer Foundation PSMA theranostics state of the science meetingThe Prostate, 2020
- 68Ga-PSMA I&T PET/CT for primary staging of prostate cancerEuropean Journal of Nuclear Medicine and Molecular Imaging, 2019
- Detection rate of PET/CT in patients with biochemical relapse of prostate cancer using [68Ga]PSMA I&T and comparison with published data of [68Ga]PSMA HBED-CCEuropean Journal of Nuclear Medicine and Molecular Imaging, 2016
- PET imaging with a [68Ga]gallium-labelled PSMA ligand for the diagnosis of prostate cancer: biodistribution in humans and first evaluation of tumour lesionsEuropean Journal of Nuclear Medicine and Molecular Imaging, 2012